Ovarian Cancer Stocks List

Ovarian Cancer Stocks Recent News

Date Stock Title
May 9 VSTM Verastem GAAP EPS of -$1.26
May 9 NKTR Nektar Therapeutics GAAP EPS of -$0.19, revenue of $21.6M
May 9 NKTR Nektar Therapeutics Reports First Quarter 2024 Financial Results
May 9 VSTM Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 9 MRUS Merus GAAP EPS of -$0.59 beats by $0.20, revenue of $7.89M misses by $0.45M
May 9 CLDX Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
May 9 MYGN Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
May 9 ACRV While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership
May 9 VERU Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
May 8 NKTR Nektar Therapeutics Q1 2024 Earnings Preview
May 8 PSTV Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
May 8 MYGN Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
May 8 MRUS Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 8 MYGN Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
May 8 MYGN Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results
May 8 VERU Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
May 8 CLDX Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 VERU Veru GAAP EPS of -$0.07 misses by $0.01, revenue of $4.14M
May 8 VERU Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
May 8 MYGN Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...
Ovarian Cancer

Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age and those who reach menopause at an older age. Other risk factors include hormone therapy after menopause, fertility medication, and obesity. Factors that decrease risk include hormonal birth control, tubal ligation, and breast feeding. About 10% of cases are related to inherited genetic risk; women with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma. There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common. These tumors are believed to start in the cells covering the ovaries, though some may form at the Fallopian tubes. Less common types of ovarian cancer include germ cell tumors and sex cord stromal tumors. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks. Those at very high risk may have their ovaries removed as a preventive measure. If caught and treated in an early stage, ovarian cancer is often curable. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions. The overall five-year survival rate in the United States is 45%. Outcomes are worse in the developing world.In 2012, new cases occurred in 239,000 women. In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer. The typical age of diagnosis is 63. Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.

Browse All Tags